In contrast, the Wnt5a-induced clonogenicity could be significantly inhibited by an addition of PKC inhibitor GF109203X in both A549 and A549/DDP cells (p < 0.01) (Figure 4), implying that the Wnt5a was able to enhance the potency of lung cancer stem cells by activation of Wnt5a/PKC pathway. The gene discussed is PRRT2; the disease is lung cancer.